DATA GRAPHICS | Product Development
Preclinical antiviral strategies for COVID-19: Data Byte
Targets and modalities of non-repurposed therapies for COVID-19
February 4, 2021 2:00 AM UTC
Behind the mAbs and repurposed antivirals in development for COVID-19 are at least 44 early stage small molecule, protein and oligonucleotide therapies that could find utility should SARS-CoV-2 become endemic or another coronavirus make the jump to humans. Both are likely scenarios.
Only one of these therapies has advanced to the clinic. Pfizer Inc. (NYSE:PFE) has the small molecule SARS-CoV-2 3C-like protease inhibitor PF-07304814 in Phase I testing. ...